81_FR_52852 81 FR 52699 - Government-Owned Inventions; Availability for Licensing

81 FR 52699 - Government-Owned Inventions; Availability for Licensing

DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health

Federal Register Volume 81, Issue 153 (August 9, 2016)

Page Range52699-52700
FR Document2016-18862

The invention listed below is owned by an agency of the U.S. Government and is available for licensing and/or co-development in the U.S. in accordance with 35 U.S.C. 209 and 37 CFR part 404 to achieve expeditious commercialization of results of federally-funded research and development. Foreign patent applications are filed on selected inventions to extend market coverage for companies and may also be available for licensing and/or co-development.

Federal Register, Volume 81 Issue 153 (Tuesday, August 9, 2016) 
[Federal Register Volume 81, Number 153 (Tuesday, August 9, 2016)]
[Notices]
[Pages 52699-52700]
From the Federal Register Online  [www.thefederalregister.org]
[FR Doc No: 2016-18862]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


Government-Owned Inventions; Availability for Licensing

AGENCY: National Institutes of Health, HHS.

ACTION: Notice

-----------------------------------------------------------------------

SUMMARY: The invention listed below is owned by an agency of the U.S. 
Government and is available for licensing and/or co-development in the 
U.S. in accordance with 35 U.S.C. 209 and 37 CFR part 404 to achieve 
expeditious commercialization of results of federally-funded research 
and development. Foreign patent applications are filed on selected 
inventions to extend market coverage for companies and may also be 
available for licensing and/or co-development.

ADDRESSES: Invention Development and Marketing Unit, Technology 
Transfer Center, National Cancer Institute, 9609 Medical Center Drive, 
Mail Stop 9702, Rockville, MD, 20850-9702.

FOR FURTHER INFORMATION CONTACT: Information on licensing and co-
development research collaborations, and copies of the U.S. patent 
applications listed below may be obtained by contacting: Attn. 
Invention Development and Marketing Unit, Technology Transfer Center, 
National Cancer Institute, 9609 Medical Center Drive, Mail Stop 9702, 
Rockville, MD, 20850-9702, Tel. 240-276-5515 or email 
ncitechtransfer@mail.nih.gov. A signed Confidential Disclosure 
Agreement may be required to receive copies of the patent applications.

SUPPLEMENTARY INFORMATION: Technology description follows.
    Title of invention: Methods of Treating or Preventing Demyelination 
Using Thrombin Inhibitors and Methods of Detecting Demyelination Using 
Neurofascin 155.
    Description of Technology: Neurofascin 155 is a cell adhesion 
molecule that attaches myelin to axolemma. Contactin-associated protein 
(Caspr) is a major component of the perinodes. Perinodal astrocytes 
regulate nodal structure and myelin thickness by regulating thrombin-
dependent cleavage of axo-glial junction attaching the outermost 
paranodal loops of myelin to the axon membrane. Agents which inhibit 
the cleavage of Neurofascin 155 or the cleavage of Caspr1 stabilize the 
node and may impede the immunological attack of myelin where the 
paranodes are attached to the axon.
    The technology is directed to methods of treating diseases 
characterized by demyelination (such as Multiple sclerosis), white 
matter injury, or conditions associated with myelin remodeling by 
administering an agent that inhibits cleavage of Neurofascin 155 or 
Caspr1. The agent could be a thrombin inhibitor, an agent that inhibits 
thrombin expression, an anti-thrombin antibody that specifically 
inhibits thrombin mediated cleavage of Neurofascin 155, a mutated 
version or fragment of Neurofascin 155 or Caspr1, antibodies to 
Neurofascin 155 or Caspr1.
    The technology also includes methods of detecting remodeling of 
myelin by detecting changes in levels of Neurofascin 125 and 
Neurofascin 30 in a biological sample, such as central spinal fluid or 
blood.
    Potential Commercial Applications: Treatment of demyelinating 
diseases, such as Multiple sclerosis.
    Treatment of diseases characterized by white matter injury or 
myelin remodeling.
    Monitoring the amount of or rate of remodeling of myelin to 
determine the efficacy of agents used demyelinating diseases.
    Value Proposition: Agents which inhibit cleavage of Neurofascin 155 
or Caspr1 or inhibit thrombin activity are a novel approach to treating 
demyelinating diseases or diseases characterized by white matter 
injury.
    The methods of detecting modification in the amount or rate of 
remodeling of myelin can be used to determine the efficacy of 
treatments of neurological disorders and are less expensive than other 
methods currently used.
    Development Stage: Pre-clinical (in vivo validation).
    Inventor(s): R. Douglas Fields https://science.nichd.nih.gov/confluence/display/snsdp/Home.
    Intellectual Property: HHS Reference No. E-151-2015/0-PCT-02.
    PCT application, PCT/US2016/027776, filed April 15, 2016 entitled 
``Methods of Treating or Preventing Demyelination Using Thrombin 
Inhibitors and Methods of Detecting Demyelination Using Neurofascin 
155''.
    Publications: 1. In preparation.
    Collaboration Opportunity: Researchers at the Eunice Kennedy 
Shriver National Institute of Child Health and Human Development 
(``NICHD''), seek CRADA partner or collaboration for development of 
agents to treat multiple sclerosis or other conditions associated with 
myelin remodeling by administering an agent that inhibits cleavage of 
Neurofascin 155 or Caspr1. The agent could be a

[[Page 52700]]

thrombin inhibitor, an agent that inhibits thrombin expression, an 
anti-thrombin antibody that specifically inhibits thrombin mediated 
cleavage of Neurofascin 155, a mutated version or fragment of 
Neurofascin 155 or Caspr1, or antibodies to Neurofascin 155 or Caspr1.
    Contact Information: Requests for copies of the patent application 
or inquiries about licensing, research collaborations, and co-
development opportunities should be sent to John D. Hewes, Ph.D., 
email: john.hewes@nih.gov.

    Dated: August 2, 2016.
John D. Hewes,
Technology Transfer Specialist, Technology Transfer Center, National 
Cancer Institute.
[FR Doc. 2016-18862 Filed 8-8-16; 8:45 am]
 BILLING CODE 4140-01-P

Federal Register / Vol. 81, No. 153 / Tuesday, August 9, 2016 / Notices 52699 Contact Person: William C. Benzing, Ph.D., DEPARTMENT OF HEALTH AND The technology is directed to methods Scientific Review Officer, Scientific Review HUMAN SERVICES of treating diseases characterized by Branch, Division of Extramural Research, demyelination (such as Multiple NINDS/ NIH/DHHS, Neuroscience Center, National Institutes of Health sclerosis), white matter injury, or 6001 Executive Blvd., Suite 3204, MSC 9529, conditions associated with myelin Bethesda, MD 20892–9529, 301–496–0660, Government-Owned Inventions; remodeling by administering an agent Benzingw@mail.nih.gov. Availability for Licensing that inhibits cleavage of Neurofascin This notice is being published less than 15 155 or Caspr1. The agent could be a days prior to the meeting due to the timing AGENCY: National Institutes of Health, HHS. thrombin inhibitor, an agent that limitations imposed by the review and inhibits thrombin expression, an anti- funding cycle. ACTION: Notice thrombin antibody that specifically Name of Committee: National Institute of inhibits thrombin mediated cleavage of Neurological Disorders and Stroke Special SUMMARY: The invention listed below is owned by an agency of the U.S. Neurofascin 155, a mutated version or Emphasis Panel; Clinician Training Program fragment of Neurofascin 155 or Caspr1, R25 Application Review. Government and is available for licensing and/or co-development in the antibodies to Neurofascin 155 or Caspr1. Date: August 17, 2016. The technology also includes methods Time: 2:00 p.m. to 8:00 p.m. U.S. in accordance with 35 U.S.C. 209 of detecting remodeling of myelin by Agenda: To review and evaluate grant and 37 CFR part 404 to achieve detecting changes in levels of applications. expeditious commercialization of Neurofascin 125 and Neurofascin 30 in Place: National Institutes of Health, results of federally-funded research and a biological sample, such as central Neuroscience Center, 6001 Executive development. Foreign patent spinal fluid or blood. Boulevard, Rockville, MD 20852 (Telephone applications are filed on selected Potential Commercial Applications: Conference Call). inventions to extend market coverage Treatment of demyelinating diseases, Contact Person: William C. Benzing, Ph.D., for companies and may also be available such as Multiple sclerosis. Scientific Review Officer, Scientific Review for licensing and/or co-development. Treatment of diseases characterized Branch, Division of Extramural Research, ADDRESSES: Invention Development and by white matter injury or myelin NINDS/NIH/DHHS, Neuroscience Center, Marketing Unit, Technology Transfer remodeling. 6001 Executive Blvd, Suite MSC 9529, Center, National Cancer Institute, 9609 Monitoring the amount of or rate of Bethesda, MD 20892–9529, 301–496–0660, Medical Center Drive, Mail Stop 9702, remodeling of myelin to determine the Benzingw@mail.nih.gov. Rockville, MD, 20850–9702. efficacy of agents used demyelinating This notice is being published less than 15 days prior to the meeting due to the timing FOR FURTHER INFORMATION CONTACT: diseases. Information on licensing and co- Value Proposition: Agents which limitations imposed by the review and development research collaborations, inhibit cleavage of Neurofascin 155 or funding cycle. and copies of the U.S. patent Caspr1 or inhibit thrombin activity are Name of Committee: National Institute of a novel approach to treating Neurological Disorders and Stroke Special applications listed below may be obtained by contacting: Attn. Invention demyelinating diseases or diseases Emphasis Panel; Biorepository Resource Development and Marketing Unit, characterized by white matter injury. Access Committee (BRAC) X01 Meeting. Technology Transfer Center, National The methods of detecting Date: August 18, 2016. Cancer Institute, 9609 Medical Center modification in the amount or rate of Time: 1:00 p.m. to 3:00 p.m. Drive, Mail Stop 9702, Rockville, MD, remodeling of myelin can be used to Agenda: To review and evaluate grant applications. 20850–9702, Tel. 240–276–5515 or determine the efficacy of treatments of Place: National Institutes of Health, email ncitechtransfer@mail.nih.gov. A neurological disorders and are less Neuroscience Center, 6001 Executive signed Confidential Disclosure expensive than other methods currently Boulevard, Rockville, MD 20852 (Telephone Agreement may be required to receive used. Conference Call). copies of the patent applications. Development Stage: Pre-clinical (in Contact Person: Joel A. Sayoff, Ph.D., vivo validation). SUPPLEMENTARY INFORMATION: Inventor(s): R. Douglas Fields https:// Scientific Review Officer, Scientific Review Technology description follows. Branch, Division of Extramural Research, science.nichd.nih.gov/confluence/ Title of invention: Methods of display/snsdp/Home. NINDS/NIH/DHHS, Neuroscience Center, Treating or Preventing Demyelination Intellectual Property: HHS Reference 6001 Executive Blvd., Suite 3204, MSC 9529, Bethesda, MD 20892–9529, 301–496–9223, Using Thrombin Inhibitors and Methods No. E–151–2015/0–PCT–02. joel.saydoff@nih.gov. of Detecting Demyelination Using PCT application, PCT/US2016/ This notice is being published less than 15 Neurofascin 155. 027776, filed April 15, 2016 entitled days prior to the meeting due to the timing Description of Technology: ‘‘Methods of Treating or Preventing limitations imposed by the review and Neurofascin 155 is a cell adhesion Demyelination Using Thrombin funding cycle. molecule that attaches myelin to Inhibitors and Methods of Detecting (Catalogue of Federal Domestic Assistance axolemma. Contactin-associated protein Demyelination Using Neurofascin 155’’. Program Nos. 93.853, Clinical Research (Caspr) is a major component of the Publications: 1. In preparation. Related to Neurological Disorders; 93.854, perinodes. Perinodal astrocytes regulate Collaboration Opportunity: Biological Basis Research in the nodal structure and myelin thickness by Researchers at the Eunice Kennedy regulating thrombin-dependent cleavage Shriver National Institute of Child asabaliauskas on DSK3SPTVN1PROD with NOTICES Neurosciences, National Institutes of Health, HHS) of axo-glial junction attaching the Health and Human Development outermost paranodal loops of myelin to (‘‘NICHD’’), seek CRADA partner or Dated: August 3, 2016. the axon membrane. Agents which collaboration for development of agents Sylvia L. Neal, inhibit the cleavage of Neurofascin 155 to treat multiple sclerosis or other Program Analyst, Office of Federal Advisory or the cleavage of Caspr1 stabilize the conditions associated with myelin Committee Policy. node and may impede the remodeling by administering an agent [FR Doc. 2016–18863 Filed 8–8–16; 8:45 am] immunological attack of myelin where that inhibits cleavage of Neurofascin BILLING CODE 4140–01–P the paranodes are attached to the axon. 155 or Caspr1. The agent could be a VerDate Sep<11>2014 20:00 Aug 08, 2016 Jkt 238001 PO 00000 Frm 00090 Fmt 4703 Sfmt 4703 E:\FR\FM\09AUN1.SGM 09AUN1

52700 Federal Register / Vol. 81, No. 153 / Tuesday, August 9, 2016 / Notices thrombin inhibitor, an agent that organizations such as schools, United States, as well as associated inhibits thrombin expression, an anti- universities, and exchange visitor organizations and individuals, who thrombin antibody that specifically programs being investigated by CTCEU overstay their period of admission or inhibits thrombin mediated cleavage of and information about individuals, otherwise violate the terms of their visa, Neurofascin 155, a mutated version or including designated school officials immigrant, or non-immigrant status fragment of Neurofascin 155 or Caspr1, (DSOs), and associates of suspected (collectively, ‘‘status violators’’). Using or antibodies to Neurofascin 155 or status violators. the LeadTrac information technology Caspr1. Additionally, DHS/ICE is issuing a (IT) system, ICE Homeland Security Contact Information: Requests for Notice of Proposed Rulemaking to Investigations (HSI), Counterterrorism copies of the patent application or exempt this system of records from and Criminal Exploitation Unit (CTCEU) inquiries about licensing, research certain provisions of the Privacy Act, collects PII from key DHS databases and collaborations, and co-development elsewhere in the Federal Register. This analyzes it to identify suspected status opportunities should be sent to John D. newly established system will be violators. This system of records Hewes, Ph.D., email: john.hewes@ included in the Department of contains records from Arrival and nih.gov. Homeland Security’s inventory of Departure Information System (ADIS), Dated: August 2, 2016. record systems. Student and Exchange Visitor DATES: Submit comments on or before Information System (SEVIS), John D. Hewes, September 8, 2016.This new system will Enforcement Integrated Database (EID/ Technology Transfer Specialist, Technology ENFORCE), TECS, Consular Transfer Center, National Cancer Institute. be effective September 8, 2016. Consolidated Database (CCD), [FR Doc. 2016–18862 Filed 8–8–16; 8:45 am] ADDRESSES: You may submit comments, Computer—Linked Application identified by docket number DHS– BILLING CODE 4140–01–P Information Management System 2016–0053 by one of the following (CLAIMS 3), Automated Biometric methods: Identification System (IDENT), and from • Federal e-Rulemaking Portal: http:// DEPARTMENT OF HOMELAND commercial databases and public www.regulations.gov. Follow the SECURITY sources. CTCEU will also use LeadTrac instructions for submitting comments. • Fax: 202–343–4010. to collect information about Office of the Secretary organizations such as schools, • Mail: Jonathan R. Cantor, Acting [Docket No. DHS–2016–0053] Chief Privacy Officer, Privacy Office, universities, and exchange visitor Department of Homeland Security, programs being investigated by CTCEU, Privacy Act of 1974; Department of Washington, DC 20528–0655. and information about individuals, Homeland Security/ICE–015 LeadTrac Instructions: All submissions received including designated school officials System of Records must include the agency name and (DSOs) and associates of suspected docket number for this rulemaking. All status violators. AGENCY: Privacy Office, Department of ICE collects information in LeadTrac Homeland Security (DHS). comments received will be posted about suspected status violators and ACTION: Notice of Privacy Act system of without change to http:// organizations to help enforce records. www.regulations.gov, including any compliance with U.S. immigration laws. personal information provided. Specifically, the information is collected SUMMARY: In accordance with the Docket: For access to the docket to and used to support the following DHS Privacy Act of 1974, the Department of read background documents or activities: Investigating and determining Homeland Security (DHS) proposes to comments received, please visit http:// immigration status of individuals; establish a new DHS system of records www.regulations.gov. identifying fraudulent schools and/or titled, ‘‘DHS/ICE–015 LeadTrac System FOR FURTHER INFORMATION CONTACT: For organizations and the people affiliated of Records.’’ This new system of records general questions, please contact: with those schools or organizations; is being created from a previously Amber Smith, Privacy Officer, (202) providing HSI and Enforcement and issued system of records, DHS/ICE 009– 732–3300, U.S. Immigration and Removal Operations (ERO) with External Investigations SORN. 73 FR Customs Enforcement, 500 12th Street information to further investigate 75452 (Dec. 11, 2008). This system of SW., Mail Stop 5004, Washington, DC suspected status violators; and carrying records allows DHS to collect and 20536, email: ICEPrivacy@dhs.gov. For out the required enforcement activity. maintain records gathered by and in the privacy questions, please contact: Some of the individuals about whom possession of U.S. Immigrations and Jonathan R. Cantor, (202) 343–1717, ICE collects information in LeadTrac, Customs Enforcement (ICE), Homeland Acting Chief Privacy Officer, Privacy such as DSOs and associates of Security Investigations (HSI), Office, Department of Homeland suspected status violators, may have Counterterrorism and Criminal Security, Washington, DC 20528–0655. lawful permanent resident (LPR) status Exploitation Unit (CTCEU) and ICE field SUPPLEMENTARY INFORMATION: or be U.S. citizens. CTCEU and Overstay offices for appropriate enforcement Analysis Unit (OAU) personnel query a action, used in the course of their duties I. Background variety of DHS and non-DHS in identifying, investigating, and taking In accordance with the Privacy Act of information systems and enter the enforcement action against foreign 1974, 5 U.S.C. 552a, the Department of results into LeadTrac to build a unified students, exchange visitors, and other Homeland Security (DHS)/U.S. picture of an individual’s entry/exit, asabaliauskas on DSK3SPTVN1PROD with NOTICES non-immigrant visitors to the United Immigration and Customs Enforcement visa, criminal, and immigration history, States who overstay their period of (ICE) proposes to establish a new DHS and will comparably process admission or otherwise violate the terms system of records titled, ‘‘DHS/ICE–015 information about associated of their visa, immigrant, or non- LeadTrac System of Records.’’ individuals and organizations. Using immigrant status (collectively, status This record system allows DHS to this assembled information, CTCEU violators) through the LeadTrac system. collect and maintain information about personnel will determine which This SORN also allows DHS to collect foreign students, exchange visitors, and individuals and organizations warrant information in LeadTrac about other non-immigrant visitors to the additional investigation for possible VerDate Sep<11>2014 20:00 Aug 08, 2016 Jkt 238001 PO 00000 Frm 00091 Fmt 4703 Sfmt 4703 E:\FR\FM\09AUN1.SGM 09AUN1


Document Created: 2016-08-09 01:10:19
Document Modified: 2016-08-09 01:10:19
CategoryRegulatory Information
CollectionFederal Register
sudoc ClassAE 2.7:
GS 4.107:
AE 2.106:
PublisherOffice of the Federal Register, National Archives and Records Administration
SectionNotices
ActionNotice
ContactInformation on licensing and co- development research collaborations, and copies of the U.S. patent applications listed below may be obtained by contacting: Attn. Invention Development and Marketing Unit, Technology Transfer Center, National Cancer Institute, 9609 Medical Center Drive, Mail Stop 9702, Rockville, MD, 20850-9702, Tel. 240-276-5515 or email [email protected] A signed Confidential Disclosure Agreement may be required to receive copies of the patent applications.
FR Citation81 FR 52699 
2025 Federal Register | Disclaimer | Privacy Policy
USC | CFR | eCFR